Bejelentkezés Regisztrálj ingyen

Last updated: 14 June 2024 at 12:24pm EST

Katherine High Net Worth



Katherine High CRSP stock SEC Form 4 insiders trading

Katherine has made over 28 trades of the CRISPR Therapeutics AG stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 188,124 units of CRSP stock worth $7,186,337 on 21 March 2019.

The largest trade he's ever made was exercising 188,124 units of CRISPR Therapeutics AG stock on 21 March 2019 worth over $7,186,337. On average, Katherine trades about 9,656 units every 32 days since 2015. As of 21 March 2019 he still owns at least 284,201 units of CRISPR Therapeutics AG stock.

You can see the complete history of Katherine High stock trades at the bottom of the page.





Katherine High biography

Dr. Katherine A. High M.D. serves as Independent Director of the Company. Dr. High is a co-founder of Spark Therapeutics, Inc. and has served as its President and a member of its board of directors since September 2014 and has served as its Head of Research & Development since September 2017. From 2004 to 2014, Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania, an Investigator at Howard Hughes Medical Institute and the Director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia. She completed a five-year term from 2000 to 2005 on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy. Dr. High holds an A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an honorary M.A. from The University of Pennsylvania. High’s experience as an executive and scientific leader in the life sciences industry qualifies her to serve on our Board of Directors.



How old is Katherine High?

Katherine High is 68, he's been the Independent Director of CRISPR Therapeutics AG since 2019. There are no older and 15 younger executives at CRISPR Therapeutics AG.

What's Katherine High's mailing address?

Katherine's mailing address filed with the SEC is 1801 AUGUSTINE CUTOFF, , WILMINGTON, DE, 19803.

Insiders trading at CRISPR Therapeutics AG

Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani és Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.



What does CRISPR Therapeutics AG do?

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.



What does CRISPR Therapeutics AG's logo look like?

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG executives and stock owners

CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: